The panel discusses long-term data showing more limited benefit of IO-IO therapy versus TKI regimens for favorable risk RCC patients and implications for their risk-adapted treatment approach.
IDE397 Combo Displays Promising Activity in MTAP-Deletion Urothelial Cancer
A manageable safety profile was observed across 2 expansion doses of the combination in urothelial cancer, consistent with known adverse effects of both drugs.
Elevating Community Oncology Care: Insights From World GU 2025
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.
Urine Glycosaminoglycan Scores Show High Sensitivity to Detect ccRCC
External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.
Episode 13: Perspectives on Optimizing Community Care at World GU 2025
Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.
Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.
FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.